Current Treatment Landscape for Patients With MF

Aaron Gerds, MD, MS, outlines how first-line treatment choice for myelofibrosis depends on symptoms, spleen size, and blood counts, while second-line choice depends on prior side effects and medical history.

EP: 1.Available Treatment Options for Patients With Higher-Risk Myelofibrosis

EP: 2.Current Unmet Needs in the Treatment of Myelofibrosis

EP: 3.Emerging Treatments for Patients With Myelofibrosis

EP: 4.Case Presentation: A 73-Year-Old Man with Myelofibrosis (MF)

EP: 5.Risk Stratification of Patients With MF

Now Viewing

EP: 6.Current Treatment Landscape for Patients With MF

EP: 7.Momelotinib in Patients With MF

EP: 8.Monitoring Patients on Treatment for MF

EP: 9.Approaches to Switching Therapies for Patients With MF

EP: 10.Factors for Consideration When Selecting a JAK Inhibitor for Patients With MF

EP: 11.Safety of Available JAK Inhibitors for Treatment of MF

EP: 12.Future of Myelofibrosis Treatments

Recent Videos